The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer

Nygård, Jan F.; Skare, Gry Baadstrand; Thoresen, Steinar

doi:10.1136/jms.9.2.86

Cited by 144 publications

(124 citation statements)

References 21 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Several studies demonstrated that cervical canser screening by Pap test reduces mortality rates. (Nygard et al, 2002;Abed et al, 2006;Aklimunnessa et al, 2006;Taylor et al, 2006). Currently, there is no organized population-based screening program available for the whole World.…”

Section: Discussionmentioning

confidence: 99%

Population-Based Cervical Screening Outcomes in Turkey over a Period of Approximately Nine and a Half Years with Emphasis on Results for Women Aged 30-34

Şengül¹,

Altınay²,

Oksuz³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Population-Based Cervical Screening Outcomes in Turkey over a Period of Approximately Nine and a Half Years with Emphasis on Results for Women Aged 30-34

Şengül¹,

Altınay²,

Oksuz³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In the Norwegian screening programme, the relative risk of CIN2+ within 2 years after an ASCUS diagnosis compared with women with a negative result was 15 to 30. 38 In the ASCUS LSIL Triage Study (ALTS) trial, the 24-month cumulative incidence of CIN3+ among women with an index smear showing ASCUS varied between 8 and 9%. 39 In a meta-analysis of the diagnostic performance of management methods for women with a prior ASCUS result, the pooled prevalent risk of CIN2+ was 10% and the risk of CIN3+ was 6%.…”

Section: Management Of Women With Atypical Squamous Cellsmentioning

confidence: 99%

European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1

et al. 2008

View full text Add to dashboard Cite

European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1The current paper presents the first part of Chapter 6 of the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. It provides guidance on how to manage women with abnormal cervical cytology. Throughout this article the Bethesda system is used for cervical cytology terminology, as the European guidelines have recommended that all systems should at least be translated into that terminology while cervical intraepithelial neoplasia (CIN) is used for histological biopsies (Cytopathology 2007; 18:213-9). A woman with a high-grade cytological lesion, a repeated low-grade lesion or with an equivocal cytology result and a positive human papillomavirus (HPV) test should be referred for colposcopy. The role of the colposcopist is to identify the source of the abnormal cells and to make an informed decision as to whether or not any treatment is required. If a patient requires treatment the colposcopist will decide which is the most appropriate method of treatment for each individual woman. The colposcopist should also organize appropriate follow-up for each woman seen. Reflex testing for high-risk HPV types of women with atypical squamous cells (ASC) of undetermined significance with referral for colposcopy of women who test positive is a first option. Repeat cytology is a second possibility. Direct referral to a gynaecologist should be restricted to special circumstances. Follow-up of low-grade squamous intraepithelial lesion is more difficult because currently there is no evidence to support any method of management as being optimal; repeat cytology and colposcopy are options, but HPV testing is not sufficiently selective, unless for older women. Women with high-grade squamous intraepithelial lesion (HSIL) or atypical squamous cells, cannot exclude HSIL (ASC-H) should be referred without triage. Women with glandular lesions require particular attention. In a subsequent issue of Cytopathology, the second part of Chapter 6 will be presented, with recommendations for management and treatment of histologically confirmed intraepithelial neoplasia and guidance for follow-up of special cases such as women who are pregnant, postmenopausal or immunocompromised.

show abstract

“…The most common cervical cancer screening method, the Papanicolaou (Pap) cervical cytology screening, has been proven to reduce cervical cancer rates dramatically through early detection of premalignant lesions (Devesa et al, 1997;Nygard et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Perceived Susceptibility, and Cervical Cancer Screening Benefits and Barriers in Malaysian Women Visiting Outpatient Clinics

Baskaran

Subramanian²,

Rahman³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer

Abstract: The coordinated screening programme provides a low cost way of increasing the coverage of the female population, and consequently has reduced the rate of invasive cervical cancer.

Cited by 144 publications

References 21 publications

Population-Based Cervical Screening Outcomes in Turkey over a Period of Approximately Nine and a Half Years with Emphasis on Results for Women Aged 30-34

Population-Based Cervical Screening Outcomes in Turkey over a Period of Approximately Nine and a Half Years with Emphasis on Results for Women Aged 30-34

European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1

Perceived Susceptibility, and Cervical Cancer Screening Benefits and Barriers in Malaysian Women Visiting Outpatient Clinics

Contact Info

Product

Resources

About